LGT Capital Partners LTD. raised its position in shares of Mednax Inc. (NYSE:MD) by 192.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 134,540 shares of the company’s stock after buying an additional 88,540 shares during the period. LGT Capital Partners LTD. owned 0.15% of Mednax worth $8,913,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of MD. Geode Capital Management LLC boosted its position in Mednax by 4.1% in the first quarter. Geode Capital Management LLC now owns 572,404 shares of the company’s stock valued at $36,966,000 after buying an additional 22,537 shares during the period. Renaissance Technologies LLC purchased a new position in Mednax during the first quarter valued at $28,536,000. Legal & General Group Plc boosted its position in Mednax by 17.4% in the first quarter. Legal & General Group Plc now owns 63,195 shares of the company’s stock valued at $4,085,000 after buying an additional 9,350 shares during the period. Metropolitan Life Insurance Co. NY boosted its position in Mednax by 2.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 87,477 shares of the company’s stock valued at $5,653,000 after buying an additional 2,200 shares during the period. Finally, Arizona State Retirement System boosted its position in Mednax by 5.8% in the first quarter. Arizona State Retirement System now owns 51,467 shares of the company’s stock valued at $3,326,000 after buying an additional 2,800 shares during the period. Hedge funds and other institutional investors own 99.62% of the company’s stock.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Mednax Inc. (NYSE:MD) traded down 0.76% during mid-day trading on Friday, hitting $63.88. 343,949 shares of the stock traded hands. Mednax Inc. has a 1-year low of $59.36 and a 1-year high of $76.96. The stock has a market cap of $5.92 billion, a price-to-earnings ratio of 17.54 and a beta of 0.62. The company’s 50 day moving average price is $64.28 and its 200-day moving average price is $67.60.

Mednax (NYSE:MD) last released its quarterly earnings data on Thursday, October 27th. The company reported $1.09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.11 by $0.02. The firm had revenue of $828 million for the quarter, compared to the consensus estimate of $821.18 million. Mednax had a net margin of 10.97% and a return on equity of 14.47%. The firm’s revenue for the quarter was up 14.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.10 earnings per share. Analysts predict that Mednax Inc. will post $4.04 earnings per share for the current year.

Several research firms recently weighed in on MD. Zacks Investment Research cut shares of Mednax from a “buy” rating to a “hold” rating in a report on Saturday, July 30th. JPMorgan Chase & Co. cut their price target on shares of Mednax from $85.00 to $80.00 and set an “overweight” rating on the stock in a report on Friday, July 29th. Citigroup Inc. cut their price target on shares of Mednax from $76.00 to $72.00 and set a “neutral” rating on the stock in a report on Wednesday, August 17th. Raymond James Financial Inc. cut shares of Mednax from an “outperform” rating to a “market perform” rating in a report on Thursday, October 27th. Finally, Mizuho reiterated a “buy” rating and issued a $79.00 target price on shares of Mednax in a research note on Tuesday, September 20th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $74.44.

In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $65.01, for a total transaction of $97,515.00. Following the completion of the sale, the director now directly owns 12,755 shares in the company, valued at approximately $829,202.55. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 2.40% of the company’s stock.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

5 Day Chart for NYSE:MD

Receive News & Stock Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related stocks with our FREE daily email newsletter.